Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Int J Gynecol Cancer ; 13(5): 664-72, 2003.
Article in English | MEDLINE | ID: mdl-14675352

ABSTRACT

The objective of this study was to evaluate the potential survival benefit of debulking macroscopic adenopathy and other clinical prognostic factors among patients with node-positive endometrial carcinoma. Demographic, operative, pathologic, and follow-up data were abstracted retrospectively for 41 eligible patients with FIGO stage IIIC endometrial cancer. Survival curves were generated using the Kaplan-Meier method and statistical comparisons were performed using the log rank test, logistic regression analysis, and the Cox proportional hazards regression model. All patients had positive pelvic lymph nodes and 20 patients (48.8%) had positive para-aortic lymph nodes. Postoperatively, all patients received whole pelvic radiation therapy, 17 received extended-field radiation therapy, and 15 patients received chemotherapy. The median disease-specific survival (DSS) time for all patients was 30.6 months (median follow-up 34. 0 months). Patients with completely resected macroscopic lymphadenopathy had a significantly longer median DSS time (37.5 months), compared to patients left with gross residual nodal disease (8.8 months, P = 0.006). On multivariate analysis, independent predictors of DSS were gross residual nodal disease (HR 7.96, 95% CI 2.54-24.97, P < 0. 001), age > or = 65 years (HR 6.22, 95% CI 2.05-18.87, P = 0.001), and the administration of adjuvant chemotherapy (HR 0.22, 95% CI 0.07-0.76, P = 0.016). We conclude that in patients with stage IIIC endometrial carcinoma, complete resection of macroscopic nodal disease and the administration of adjuvant chemotherapy, in addition to directed radiation therapy, are associated with improved survival.


Subject(s)
Endometrial Neoplasms/mortality , Endometrial Neoplasms/surgery , Lymph Nodes/surgery , Neoplasm Recurrence, Local/mortality , Neoplasm Recurrence, Local/surgery , Adenocarcinoma, Clear Cell/mortality , Adenocarcinoma, Clear Cell/pathology , Adenocarcinoma, Clear Cell/surgery , Adult , Aged , Aorta, Thoracic , Carcinoma, Endometrioid/mortality , Carcinoma, Endometrioid/pathology , Carcinoma, Endometrioid/surgery , Combined Modality Therapy , Cystadenocarcinoma, Serous/mortality , Cystadenocarcinoma, Serous/pathology , Cystadenocarcinoma, Serous/surgery , Disease-Free Survival , Endometrial Neoplasms/pathology , Female , Humans , Lymph Node Excision , Lymph Nodes/pathology , Lymphatic Metastasis , Maryland/epidemiology , Middle Aged , Neoplasm Recurrence, Local/pathology , Neoplasm Staging , Pelvis , Proportional Hazards Models , Survival Analysis
2.
Int J Gynecol Cancer ; 13(4): 528-31, 2003.
Article in English | MEDLINE | ID: mdl-12911733

ABSTRACT

The purpose of this study is to report clinical aspects and treatment results of patients seen at Johns Hopkins. A search of the tumor registry of the Sidney Kimmel Comprehensive Cancer Center found 453 patients with malignancies of the vulva registered between 1977 and 1997. Patient and tumor characteristics, treatment methods, and follow-up were obtained from charts. Seven patients were identified with sarcoma of the vulva. Of these, one was removed from analysis due to histology. Three patients had leiomyosarcoma, two had fibrosarcoma, and one had epithelioid sarcoma. The mean age was 41. Mean time to diagnosis was 6 months. All but one of the tumors was located on the labia majora. Median tumor size was 3.5 cm. Surgery varied from wide local excision to radical vulvectomy with inguinal lymph node dissection. Surgical margins were microscopically negative in five of the six cases. Two patients had received adjuvant external beam radiation. One of them had a tumor greater than 5 cm and close surgical margins and the other had high-grade tumor, which recurred after previous surgery. Mean follow-up was 127.8 months. There have been no recurrences to date.


Subject(s)
Soft Tissue Neoplasms/pathology , Soft Tissue Neoplasms/therapy , Vulvar Neoplasms/pathology , Vulvar Neoplasms/therapy , Adolescent , Adult , Chemotherapy, Adjuvant , Cohort Studies , Combined Modality Therapy , Female , Fibrosarcoma/mortality , Fibrosarcoma/pathology , Fibrosarcoma/therapy , Follow-Up Studies , Gynecologic Surgical Procedures/methods , Humans , Leiomyosarcoma/mortality , Leiomyosarcoma/pathology , Leiomyosarcoma/therapy , Middle Aged , Neoplasm Staging , Radiotherapy, Adjuvant , Registries , Risk Assessment , Soft Tissue Neoplasms/mortality , Survival Analysis , Treatment Outcome , Vulvar Neoplasms/mortality
3.
Int J Radiat Oncol Biol Phys ; 47(3): 655-60, 2000 Jun 01.
Article in English | MEDLINE | ID: mdl-10837948

ABSTRACT

PURPOSE: To examine prostate and seminal vesicles position late in the course of radiation therapy and to determine the effect and predictive value of the bladder and rectum on prostate and seminal vesicles positioning. METHODS AND MATERIALS: Twenty-four patients with localized prostate cancer underwent a computerized tomography scan (CT1) before the start of radiation therapy. After 4-5 weeks of radiation therapy, a second CT scan (CT2) was obtained. All patients were scanned in the supine treatment position with instructions to maintain a full bladder. The prostate, seminal vesicles, bladder, and rectum were contoured. CT2 was aligned via fixed bony anatomy to CT1. The geometrical center and volume of each structure were obtained and directly compared. RESULTS: The prostate shifted along a diagonal axis extending from an anterior-superior position to a posterior-inferior position. The dominant shift was to a more posterior-inferior position. On average, bladder and rectal volumes decreased to 51% (+/-29%) and 82% (+/-45%) of their pretreatment values, respectively. Multiple regression analysis (MRA) revealed that bladder movement and volume change and upper rectum movement were independently associated with prostate motion (p = 0.016, p = 0. 003, and p = 0.052 respectively). CONCLUSION: Patients are often instructed to maintain a full bladder during a course of external beam radiation therapy, in the hopes of decreasing bladder and small bowel toxicity. However, our study shows that large bladder volumes late in therapy are strongly associated with posterior prostate displacement. This prostate displacement may result in marginal miss.


Subject(s)
Prostate/diagnostic imaging , Prostatic Neoplasms/radiotherapy , Seminal Vesicles/diagnostic imaging , Humans , Male , Movement , Prostatic Neoplasms/diagnostic imaging , Radiotherapy, Conformal , Rectum/diagnostic imaging , Regression Analysis , Tomography, X-Ray Computed , Urinary Bladder/diagnostic imaging
4.
J Clin Oncol ; 18(9): 1906-13, 2000 May.
Article in English | MEDLINE | ID: mdl-10784631

ABSTRACT

PURPOSE: The loss of p53 function is a recognized adverse prognostic factor in invasive breast cancer. Several studies have shown a relationship between the nuclear accumulation of p53 protein (a surrogate marker of p53 inactivation) and poor disease-free and overall survival. In general, however, these studies did not report the prognostic value of p53 for local failure, which we have therefore assessed retrospectively here. MATERIALS AND METHODS: Accumulation of p53 protein was evaluated by immunohistochemistry in 1,530 mastectomy-treated breast cancer patients (259 radiation therapy [RT]- and 1,271 mastectomy only [No RT]-treated patients). Statistical comparisons were made between p53 protein accumulation, estrogen/progesterone receptors, nodal status, tumor size, and local failure rate (LFR). Local failure was defined as tumor recurrence involving the chest wall and/or the ipsilateral supraclavicular/axillary lymph nodes. The median follow-up period was 62 months. RESULTS: In the No RT group, the LFR was 9.1% and 16. 5% in p53-negative and p53-positive patients, respectively (P<.001). Multivariate analysis revealed that p53 protein accumulation was significantly associated with an increased risk of local relapse (relative risk [RR], 1.7; 95% confidence interval [CI], 1.2 to 2.4). Nodal status and tumor size were also significant factors. In the RT group, the LFR was 9.3% and 21.5% in p53-negative and p53-positive patients, respectively (P = .009). Multivariate analysis revealed that p53 protein accumulation was significantly associated with an increased risk of local relapse (RR, 2.5; 95% CI, 1.1 to 5.7), as was nodal status. CONCLUSION: Nuclear accumulation of p53 protein is independently associated with a significantly increased local failure rate in breast cancer patients treated with mastectomy, with or without radiation.


Subject(s)
Breast Neoplasms/genetics , Genes, p53/genetics , Neoplasm Recurrence, Local , Tumor Suppressor Protein p53/analysis , Adult , Aged , Breast Neoplasms/pathology , Breast Neoplasms/surgery , Disease-Free Survival , Female , Humans , Immunohistochemistry , Mastectomy, Radical , Middle Aged , Predictive Value of Tests , Prognosis , Retrospective Studies
5.
J Clin Microbiol ; 37(12): 3896-900, 1999 Dec.
Article in English | MEDLINE | ID: mdl-10565903

ABSTRACT

Oral mucosal colonization and infection with Candida are common in patients receiving radiation therapy for head and neck cancer. Infection is marked by oral pain and/or burning and can lead to significant patient morbidity. The purpose of this study was to identify Candida strain diversity in this population by using a chromogenic medium, subculturing, molecular typing, and antifungal susceptibility testing of clinical isolates. These results were then correlated with clinical outcome in patients treated with fluconazole for infection. Specimens from 30 patients receiving radiation therapy for head and neck cancer were cultured weekly for Candida. Patients exhibiting clinical infection were treated with oral fluconazole. All isolates were plated on CHROMagar Candida and RPMI medium, subcultured, and submitted for antifungal susceptibility testing and molecular typing. Infections occurred in 27% of the patients and were predominantly due to Candida albicans (78%). Candida carriage occurred in 73% of patients and at 51% of patient visits. Yeasts other than C. albicans predominated in carriage, as they were isolated from 59% of patients and at 52% of patient visits. All infections responded clinically, and all isolates were susceptible to fluconazole. Molecular typing showed that most patients had similar strains throughout their radiation treatment. One patient, however, did show the acquisition of a new strain. With this high rate of infection (27%), prophylaxis to prevent infection should be evaluated for these patients.


Subject(s)
Candida/classification , Candidiasis, Oral/epidemiology , Head and Neck Neoplasms/radiotherapy , Antifungal Agents/pharmacology , Antifungal Agents/therapeutic use , Candida/drug effects , Candida/genetics , Candida/isolation & purification , Candidiasis, Oral/drug therapy , Candidiasis, Oral/microbiology , Culture Media , Fluconazole/pharmacology , Fluconazole/therapeutic use , Karyotyping , Microbial Sensitivity Tests , Mouth Mucosa/microbiology , Mycological Typing Techniques , Polymorphism, Restriction Fragment Length , Radiation Dosage , Radiotherapy/adverse effects
6.
Mol Pharmacol ; 52(4): 600-5, 1997 Oct.
Article in English | MEDLINE | ID: mdl-9380022

ABSTRACT

We have examined the effects of conditionally expressing wild-type p53 activity in HT29 cells on DNA damage and cytotoxicity caused by exposure to fluorodeoxyuridine (FdUrd). Expression of wild-type p53 phenotype for 24 hr before FdUrd treatment provided HT29 cells with virtually complete protection from cytotoxicity caused by this drug. In addition, wild-type p53 expression also prevented FdUrd-induced DNA double-strand breaks and, unexpectedly, single-strand breaks in parental (mature) DNA. Temporary expression of wild-type p53 activity in the absence of drug treatment caused some loss of clonogenicity, although the magnitude of this cytotoxic effect was small compared with the level of cell kill obtained by treatment with cytotoxic drugs for similar periods of time, indicating that HT29 cells are not highly sensitive to induction of programmed cell death by wild-type p53. Because these observations conflict with previously suggested models for FdUrd-induced damage to parental DNA, we propose an alternative model to explain how incorporation of uracil into nascent DNA might result in single-strand breaks in the opposite (parental) strand and how these breaks might be converted to the double-strand breaks that produce cell death.


Subject(s)
Antimetabolites, Antineoplastic/pharmacology , Colonic Neoplasms/pathology , DNA Damage , Floxuridine/pharmacology , Genes, p53 , Animals , Cell Cycle , Colonic Neoplasms/genetics , Electrophoresis, Gel, Pulsed-Field , HT29 Cells , Humans , Mice , Phenotype
7.
Radiat Oncol Investig ; 5(2): 43-9, 1997.
Article in English | MEDLINE | ID: mdl-9303056

ABSTRACT

Substantial controversy surrounds our understanding of the effect of p53 status on radiation sensitivity. To assess directly the role of p53 expression on radiation sensitivity, we chose a conditional expression system using a temperature-sensitive murine p53 that permitted each cell line to act as its own control. We found that the conditional expression of wild type p53 induced cell death (both apoptotic and nonapoptotic), changes in cell cycle distribution (arrest in G1 and G2, which resulted in a marked depletion of S-phase cells and an increase in the fraction of cells in G2), and an increase in the radiation resistance of G1 cells. These counterbalancing effects resulted in no significant effect on overall radiosensitivity. These findings demonstrate that wild type p53 function can produce a variety of effects that can modulate radiation sensitivity and may explain why p53 status alone has not been a strong predictor of radiosensitivity.


Subject(s)
HT29 Cells/radiation effects , Radiation Tolerance/physiology , Tumor Suppressor Protein p53/biosynthesis , Apoptosis/radiation effects , Biomarkers, Tumor/radiation effects , Cell Cycle/radiation effects , Cell Death , Cell Survival/radiation effects , Dose-Response Relationship, Radiation , Flow Cytometry , HT29 Cells/metabolism , HT29 Cells/pathology , Humans , Predictive Value of Tests
SELECTION OF CITATIONS
SEARCH DETAIL
...